Craig Crews, a Yale professor and serial entrepreneur, has developed a model through PITCH (Program in Innovative Therapeutics for CT's Health), a biotech accelerator he founded, to translate academic discoveries into biopharma ventures and navigate the 'valley of death'.34
On March 4, 2026, recent coverage highlighted Crews' approach in guiding startups like Proteolix (2003, led to FDA-approved Kyprolis), Arvinas (2013), and Halda Therapeutics (2018, acquired by Johnson & Johnson).3124
Crews' work focuses on targeted protein degradation technologies, including PROTACs and RIPTAC 'hold-and-kill' therapeutics at Halda, aimed at cancer treatments like prostate cancer.124
His efforts strengthen New Haven's biotech ecosystem by creating jobs and bridging academia-industry gaps.2
Sources:
1. https://www.biopharmadive.com/news/halda-therapeutics-biotech-startup-craig-crews/642551/
2. https://news.yale.edu/2025/12/01/pioneering-drug-development-one-company-time
3. https://endpoints488.rssing.com/chan-79233195/article6237.html?nocache=0